Suppr超能文献

低血压和心动过缓——吡贝地尔的一种严重不良反应:病例报告及文献综述

Hypotension and bradycardia, a serious adverse effect of piribedil, a case report and literature review.

作者信息

Zhang Piao, Li Yan, Nie Kun, Wang Lijuan, Zhang Yuhu

机构信息

Department of Neurology, Guangdong Neuroscience Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong province, China.

The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, Guangdong province, China.

出版信息

BMC Neurol. 2018 Dec 27;18(1):221. doi: 10.1186/s12883-018-1230-1.

Abstract

BACKGROUND

Dopamine agonists (DAs) are efficacious for the treatment of motor and nonmotor symptoms in patients with Parkinson's disease (PD). The treatment of PD with DAs is often complicated by adverse drug reactions (ADRs) of dopaminergic and non-dopaminergic origins. The DA piribedil is widely used in Asian, European, and Latin American countries; therefore, its ADRs are pertinent to clinicians. Here we present a rare case of hypotension and bradycardia that is significantly related to the dosage of piribedil.

CASE PRESENTATION

A middle-aged male, diagnosed with PD, received dopamine replacement with piribedil. When taking 50 mg piribedil daily dose, the patient didn't feel any discomfort. Two hours after taking 100 mg piribedil he presented with serious concomitant hypotension and bradycardia with a blood pressure (BP) reading of 85/48 mmHg and a heart rate (HR) of 45 beats/min when sitting. After taking 75 mg piribedil, the patient showed the same symptoms with BP reading at 70/45 mmHg and HR of 47 beats/min in the same position. Upon replacing treatment with pramipexole 0.125 mg, 0.25 mg, and 0.375 mg three times a day, no further cardiovascular effects persisted.

CONCLUSIONS

No studies have previously reported the simultaneous observation of position-unrelated hypotension and bradycardia after taking small doses of piribedil. More studies are needed to explore the effects of DAs on BP and HR, especially piribedil. Piribedil is efficacious for the treatment of PD, but it is important to weigh the potential risk of hypotension and bradycardia against the clinical benefits of this drug.

摘要

背景

多巴胺激动剂(DAs)对帕金森病(PD)患者的运动和非运动症状治疗有效。使用DAs治疗PD常因多巴胺能和非多巴胺能来源的药物不良反应(ADRs)而变得复杂。DA类药物吡贝地尔在亚洲、欧洲和拉丁美洲国家广泛使用;因此,其ADRs与临床医生密切相关。在此,我们报告一例罕见的与吡贝地尔剂量显著相关的低血压和心动过缓病例。

病例介绍

一名中年男性,被诊断为PD,接受吡贝地尔进行多巴胺替代治疗。当每日服用50mg吡贝地尔时,患者未感到任何不适。服用100mg吡贝地尔两小时后,患者出现严重的低血压和心动过缓,坐位时血压(BP)为85/48mmHg,心率(HR)为45次/分钟。服用75mg吡贝地尔后,患者在相同体位出现相同症状,血压为70/45mmHg,心率为47次/分钟。当改为每天三次服用0.125mg、0.25mg和0.375mg的普拉克索治疗后,未再出现进一步的心血管效应。

结论

此前尚无研究报道服用小剂量吡贝地尔后同时出现与体位无关的低血压和心动过缓。需要更多研究来探索DAs对血压和心率的影响,尤其是吡贝地尔。吡贝地尔对PD治疗有效,但权衡该药物低血压和心动过缓的潜在风险与临床益处非常重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4768/6307137/a7f012756c13/12883_2018_1230_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验